| First Author | Emmanouilidou E | Year | 2011 |
| Journal | PLoS One | Volume | 6 |
| Issue | 7 | Pages | e22225 |
| PubMed ID | 21779395 | Mgi Jnum | J:175787 |
| Mgi Id | MGI:5287321 | Doi | 10.1371/journal.pone.0022225 |
| Citation | Emmanouilidou E, et al. (2011) Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS One 6(7):e22225 |
| abstractText | Genetic, biochemical, and animal model studies strongly suggest a central role for alpha-synuclein in the pathogenesis of Parkinson's disease. alpha-synuclein lacks a signal peptide sequence and has thus been considered a cytosolic protein. Recent data has suggested that the protein may be released from cells via a non-classical secretory pathway and may therefore exert paracrine effects in the extracellular environment. However, proof that alpha-synuclein is actually secreted into the brain extracellular space in vivo has not been obtained. We developed a novel highly sensitive ELISA in conjugation with an in vivo microdialysis technique to measure alpha-synuclein in brain interstitial fluid. We show for the first time that alpha-synuclein is readily detected in the interstitial fluid of both alpha-synuclein transgenic mice and human patients with traumatic brain injury. Our data suggest that alpha-synuclein is physiologically secreted by neurons in vivo. This interstitial fluid pool of the protein may have a role in the propagation of synuclein pathology and progression of Parkinson's disease. |
